Reinhard Dummer

Reinhard Dummer

UNVERIFIED PROFILE

Are you Reinhard Dummer?   Register this Author

Register author
Reinhard Dummer

Reinhard Dummer

Publications by authors named "Reinhard Dummer"

Are you Reinhard Dummer?   Register this Author

100Publications

5071Reads

47Profile Views

Efficacy and safety of Colchicine in inflammatory skin diseases: a retrospective, monocentric study in a large tertiary center.

J Dermatolog Treat 2019 Nov 7:1-25. Epub 2019 Nov 7.

Dermatology University Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2019.1690621DOI Listing
November 2019

Use of Lasers for Iron-Induced Accidental Tattoos: Experience at a Tertiary Referral Center.

Dermatol Surg 2019 Nov 6. Epub 2019 Nov 6.

All authors are affiliated with the Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DSS.0000000000002262DOI Listing
November 2019

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

N Engl J Med 2019 10 28;381(16):1535-1546. Epub 2019 Sep 28.

From the Royal Marsden NHS Foundation Trust, London (J.L.), and the College of Medicine, Swansea University, Swansea (J.W.) - both in the United Kingdom; the Oncology Institute of Veneto IRCCS, Padua (V.C.-S.), the European Institute of Oncology, IRCCS, Milan (P.F.F.), Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples (P.A.A.), the Immunotherapy and Somatic Cell Therapy Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (M.G.), and the Center for Immuno-Oncology, Medical Oncology and Immunotherapy, University Hospital, Siena (M.M.) - all in Italy; the University of Colorado Cancer Center, Aurora (R.G.); Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille Hôpital Timone, Marseille (J.-J.G.), and Université de Paris, INSERM Unité 976, Assistance Publique-Hôpitaux de Paris Dermatology and Centres d'Investigation Clinique, Saint Louis Hospital, Paris (C.L.) - both in France; the Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); the University of Michigan, Ann Arbor (C.D.L.); Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas (C.L.C.); the Department of Dermatology, University of Essen, Essen, and the German Cancer Consortium, Heidelberg - both in Germany (D.S.); Universitäts Spital, Zurich, Switzerland (R.D.); Cross Cancer Institute, Edmonton, AB (M.S.), and the Princess Margaret Cancer Centre, Toronto (D.H.) - both in Canada; Tasman Oncology Research, Southport, QLD (A.H.), the Crown Princess Mary Cancer Centre, Melanoma Institute Australia, University of Sydney, Sydney, NSW (M.S.C., G.V.L.), and the Royal North Shore and Mater Hospitals (G.V.L.), Sydney, and the Peter MacCallum Cancer Centre, Melbourne, VIC (G.M.) - all in Australia; General University Hospital Gregorio Marañon and Centro de Investigación Biomédica en Red de Oncología, Madrid (I.M.-R.); the Netherlands Cancer Institute, Amsterdam (J.H.); the Leuven Cancer Institute, Department of General Medical Oncology, University Hospital Leuven, Leuven, Belgium (P.S.); University of California San Diego Health-La Jolla Moores Cancer Center, La Jolla (G.A.D.); the Department of Oncology, Odense University Hospital, Odense, Denmark (L.B.); Bristol-Myers Squibb, Princeton, NJ (J.I.R., A.B., A.M.); Dana-Farber Cancer Institute, Boston (F.S.H.); and the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.D.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1910836DOI Listing
October 2019

Hair Depigmentation and Hair Loss in Advanced Melanoma Treated with Combined Immunotherapy and Targeted Therapy.

Acta Derm Venereol 2019 Oct 18. Epub 2019 Oct 18.

Department of Dermatology , University Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3355DOI Listing
October 2019

Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update.

Expert Opin Investig Drugs 2019 Sep 18;28(9):799-809. Epub 2019 Aug 18.

Department of Dermatology, University Hospital of Zurich , Zurich , Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2019.1654995DOI Listing
September 2019

Dapsone in a Large Tertiary Center: Outdated Therapeutic Option or Timeless Agent?

Dermatology 2019 Sep 11:1-8. Epub 2019 Sep 11.

Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000502256DOI Listing
September 2019

Serum S100B Levels in Melanoma.

Methods Mol Biol 2019 ;1929:691-700

Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/978-1-4939-9030-6_43
Publisher Site
http://dx.doi.org/10.1007/978-1-4939-9030-6_43DOI Listing
July 2019

Osteoblasts contribute to a protective niche that supports melanoma cell proliferation and survival.

Pigment Cell Melanoma Res 2019 Jul 19. Epub 2019 Jul 19.

Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12812DOI Listing
July 2019

Is single versus combination therapy problematic in the treatment of cutaneous melanoma?

Expert Rev Clin Pharmacol 2019 Jul 31. Epub 2019 Jul 31.

a Department of Dermatology, University Hospital Zurich , Gloriastrasse 31, 8091 Zurich , Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1650641DOI Listing
July 2019

How I treat metastatic melanoma.

ESMO Open 2019 21;4(Suppl 2):e000509. Epub 2019 Jul 21.

Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2019-000509DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677980PMC
July 2019

Potassium Iodide for Cutaneous Inflammatory Disorders: A Monocentric, Retrospective Study.

Dermatology 2019 21;235(2):137-143. Epub 2018 Nov 21.

Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000494614DOI Listing
June 2019

Rapidly Evolving Extensive Fluorodeoxyglucose-Positive Soft-Tissue Activity During Nivolumab Therapy.

JAMA Oncol 2019 May;5(5):730-731

Department of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2018.6431DOI Listing
May 2019

Reply to E. Hindié and K.R. Hess.

J Clin Oncol 2019 May 2;37(15):1356-1358. Epub 2019 Apr 2.

Georgina V. Long, MD, PhD, Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia; Reinhard Dummer, MD, University Hospital Zürich Skin Cancer Center, Zürich, Switzerland; Dirk Schadendorf, MD, PhD, University Hospital Essen, Essen, Germany, and German Cancer Consortium, Heidelberg, Germany; Mario Santinami, MD, Fondazione Istituto Nazionale Tumori, Milan, Italy; Victoria Atkinson, MD, Princess Alexandra Hospital, Gallipoli Medical Research Foundation, and University of Queensland, Brisbane, QLD, Australia; Mario Mandalà, MD, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy; Vanna Chiarion-Sileni, MD, Veneto Institute of Oncology-Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy; James Larkin, MD, PhD, Royal Marsden National Health Service Foundation Trust, London, United Kingdom; Marta Nyakas, MD, Oslo University Hospital, Oslo, Norway; Caroline Dutriaux, MD, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux, France; Andrew Haydon, MD, PhD, The Alfred Hospital, Melbourne, VIC, Australia; Caroline Robert, MD, PhD, Institute Gustave Roussy, Paris, France; Laurent Mortier, MD, PhD, Université de Lille, Institut National de la Santé et de la Recherche Médicale U 1189, Centre Hospitalier Universitaire Lille, Lille, France; Jacob Schachter, MD, PhD, Sheba Medical Center, Tel HaShomer, Israel, and Tel Aviv University, Tel Aviv, Israel; Thierry Lesimple, MD, MSc, Centre Eugène Marquis, Rennes, France; Ruth Plummer, MD, PhD, Freeman Hospital and Newcastle University, Newcastle upon Tyne, United Kingdom; Kohinoor Dasgupta, PhD, Novartis Healthcare, Hyderabad, India; Tomas Haas, PhD, Novartis AG, Basel, Switzerland; Mark Shilkrut, MD, PhD and Eduard Gasal, MD, Novartis Pharmaceuticals, East Hanover, NJ; Richard Kefford, MD, PhD, Melanoma Institute Australia, The University of Sydney, Macquarie University, and Westmead Hospital, Sydney, NSW, Australia; John M. Kirkwood, MD, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA; and Axel Hauschild, MD, University Hospital Schleswig-Holstein, Kiel, Germany.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.19.00004
Publisher Site
http://dx.doi.org/10.1200/JCO.19.00004DOI Listing
May 2019

Radiotherapy in Periocular Cutaneous Malignancies: A Retrospective Study.

Dermatology 2019 2;235(3):234-239. Epub 2019 Apr 2.

Department of Dermatology, University Hospital Zurich, Zurich, Switzerland,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496539DOI Listing
April 2019

Regulatory T Cells Restrain Pathogenic T Helper Cells during Skin Inflammation.

Cell Rep 2018 12;25(13):3564-3572.e4

Institute of Experimental Immunology, Department of Inflammation Research, University of Zurich, 8057 Zurich, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S22111247183192
Publisher Site
http://dx.doi.org/10.1016/j.celrep.2018.12.012DOI Listing
December 2018

Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe.

Eur J Dermatol 2018 Dec;28(6):736-749

Skin Cancer Centre/Dermatology Clinic, Universitätsspital Zürich, Zürich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/ejd.2018.3447DOI Listing
December 2018

Evaluation of the National Swiss Skin Cancer Screening Campaign 2013: Do We Do the Right Thing.

Dermatology 2017 14;233(5):404-409. Epub 2017 Dec 14.

Department of Dermatology, University of Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000484946DOI Listing
October 2018

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma.

J Clin Oncol 2018 Oct 22:JCO1801219. Epub 2018 Oct 22.

Axel Hauschild, University Hospital Schleswig-Holstein, Kiel; Dirk Schadendorf, University Hospital Essen, Essen; German Cancer Consortium, Heidelberg, Germany; Reinhard Dummer, University Hospital Zürich Skin Cancer Center, Zürich; Tomas Haas, Novartis AG, Basel, Switzerland; Mario Santinami, Fondazione Istituto Nazionale Tumori, Milan; Mario Mandalà, Papa Giovanni XXIII Cancer Center Hospital, Bergamo; Vanna Chiarion-Sileni, Veneto Institute of Oncology-Istituto di Ricovero e Cura a Carattere Scientifico, Padova, Italy; Victoria Atkinson, Princess Alexandra Hospital; Gallipoli Medical Research Foundation; University of Queensland, Brisbane, Queensland; Andrew Haydon, The Alfred Hospital, Melbourne, Victoria; Richard Kefford, Macquarie University; Westmead Hospital; Richard Kefford and Georgina V. Long, Melanoma Institute Australia; University of Sydney; Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia; James Larkin, Royal Marsden National Health Service Foundation Trust, London; Ruth Plummer, Freeman Hospital and Newcastle University, Newcastle upon Tyne, United Kingdom; Marta Nyakas, Oslo University Hospital, Oslo, Norway; Caroline Dutriaux, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux; Caroline Robert, Institute Gustave Roussy, Paris; Laurent Mortier, Université de Lille, Institut National de la Santé et de la Recherche Médicale U1189, Centre Hospitalier Universitaire de sa Region Lille, Lille; Thierry Lesimple, Centre Eugène Marquis, Rennes, France; Jacob Schachter, Sheba Medical Center, Tel Hashomer; Tel Aviv University, Tel Aviv, Israel; Kohinoor Dasgupta, Novartis Healthcare, Hyderabad, India; Mark Shilkrut and Eduard Gasal, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and John M. Kirkwood, UPMC Hillman Cancer Center; University of Pittsburgh, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.01219
Publisher Site
http://dx.doi.org/10.1200/JCO.18.01219DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286159PMC
October 2018

A new B-Raf inhibitor combo for advanced melanoma.

Oncotarget 2018 Oct 2;9(77):34457-34458. Epub 2018 Oct 2.

Reinhard Dummer: Department of Dermatology, University Hospital Zurich, Switzerland; University of Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26171DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6195377PMC
October 2018

The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe.

Curr Oncol Rep 2018 09 24;20(11):87. Epub 2018 Sep 24.

Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, 8091, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-018-0732-8
Publisher Site
http://dx.doi.org/10.1007/s11912-018-0732-8DOI Listing
September 2018

Successful Use of Grenz Rays for Disseminated Superficial Actinic Porokeratosis: Report of 8 Cases.

Dermatology 2017 18;233(2-3):217-222. Epub 2017 Aug 18.

Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/478855
Publisher Site
http://dx.doi.org/10.1159/000478855DOI Listing
July 2018

MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.

Eur J Cancer 2018 07 26;98:10-16. Epub 2018 May 26.

Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Ulmenweg 18, 91054 Erlangen, Germany. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09598049183081
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2018.04.010DOI Listing
July 2018

EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation.

Cancer Cell 2018 07 28;34(1):69-84.e14. Epub 2018 Jun 28.

Stem Cell Biology, Institute of Anatomy, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2018.06.001DOI Listing
July 2018

Immunological effects of BRAF+MEK inhibition.

Oncoimmunology 2018 23;7(9):e1468955. Epub 2018 Jul 23.

Department of Dermatology, University Hospital Zürich Skin Cancer Center, Zürich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2018.1468955DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140547PMC
July 2018

Methadone-Not a magic bullet in melanoma therapy.

Exp Dermatol 2018 06;27(6):694-696

Department of Dermatology, Zurich University Hospital, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/exd.13543DOI Listing
June 2018

The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis.

J Dermatol Sci 2018 Jun 15;90(3):343-356. Epub 2018 Mar 15.

Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, Alabama, 35294, USA; Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama, 35294, USA; Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, 35294, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdermsci.2018.03.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329374PMC
June 2018

Diagnostic value of F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site.

Eur J Cancer 2018 06 17;96:64-72. Epub 2018 Apr 17.

Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Frauenklinikstrasse 26, CH-8091, Zurich, Switzerland; Neuro-oncology, Department of Neurosurgery, University Hospital Lille, Salengro Hospital, Rue Emile Laine, FR-59037, Lille, France; Neurology, Department of Medical Oncology, Oscar Lambret Center, FR-59020, Lille, France; Inserm U-1192, Villeneuve d'Ascq, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.03.010DOI Listing
June 2018

Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma.

Eur J Cancer 2018 04 12;93:147-149. Epub 2018 Feb 12.

APHP Dermatology, Department of Dermatology and CIC, Paris 7 Diderot University, INSERM U976, Hôpital Saint-Louis, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.01.062DOI Listing
April 2018

The dynamics of medical care in skin cancers.

Authors:
Reinhard Dummer

Curr Opin Oncol 2018 03;30(2):105-106

Department of Dermatology, University Hospital of Zurich, University Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000435DOI Listing
March 2018

Development of encorafenib for BRAF-mutated advanced melanoma.

Curr Opin Oncol 2018 03;30(2):125-133

Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00001622-900000000-9927
Publisher Site
http://dx.doi.org/10.1097/CCO.0000000000000426DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815646PMC
March 2018

Ipilimumab and early signs of pulmonary toxicity in patients with metastastic melanoma: a prospective observational study.

Cancer Immunol Immunother 2018 01 5;67(1):127-134. Epub 2017 Oct 5.

Department of Pulmonology, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-017-2071-2DOI Listing
January 2018

low neurotrophin receptor CD271 regulates phenotype switching in melanoma.

Nat Commun 2017 12 7;8(1):1988. Epub 2017 Dec 7.

University of Zürich, Institute of Anatomy, Winterthurerstrasse 190, 8057, Zürich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-017-01573-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5719420PMC
December 2017

HLA-A*26 Is Correlated With Response to Nivolumab in Japanese Melanoma Patients.

J Invest Dermatol 2017 11 21;137(11):2443-2444. Epub 2017 Jul 21.

Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan; Singapore Immunology Network (SIgN) and Institute of Medical Biology, Agency for Science, Technology and Research (A*STAR), Biopolis, Singapore. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2017.06.023DOI Listing
November 2017

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.

N Engl J Med 2017 11 10;377(19):1813-1823. Epub 2017 Sep 10.

From the Melanoma Institute Australia, University of Sydney, Royal North Shore and Mater Hospitals (G.V.L.), and Macquarie University, Melanoma Institute Australia, University of Sydney, and Westmead Hospital (R.K.), Sydney, Princess Alexandra Hospital, Gallipoli Medical Research Foundation, University of Queensland, Brisbane (V.A.), and Alfred Hospital, Melbourne, VIC (A. Haydon) - all in Australia; University Hospital Schleswig-Holstein, Kiel (A. Hauschild), and University Hospital Essen, Essen, and the German Cancer Consortium, Heidelberg (D.S.) - all in Germany; Fondazione Istituto Nazionale Tumori, Milan (M.S.), Papa Giovanni XXIII Cancer Center Hospital, Bergamo (M.M.), and the Melanoma Oncology Unit, Veneto Oncology Institute, Padua (V.C.-S.) - all in Italy; Rikshospitalet-Radiumhospitalet, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux (C.D.), Institute Gustave Roussy, Paris (C.R.), Université de Lille, INSERM Unité 1189, Centre Hospitalier Régional Universitaire de Lille, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; Ella Institute for Melanoma, Sheba Medical Center, Tel Hashomer, Israel (J.S.); Royal Marsden NHS Foundation Trust, London (J. Larkin), and Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne (R.P.) - both in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (R.J., P.Z., B.M., J. Legos); University Hospital Zürich Skin Cancer Center, Zurich, Switzerland (R.D.); and the Melanoma Program, Hillman UPMC Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1708539
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1708539DOI Listing
November 2017

The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.

Eur J Cancer 2017 11 29;86:101-105. Epub 2017 Sep 29.

University Hospital Zürich, Department of Dermatology, Zürich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.09.014DOI Listing
November 2017

Electrical Impedance Spectroscopy in Skin Cancer Diagnosis.

Dermatol Clin 2017 Oct 7;35(4):489-493. Epub 2017 Aug 7.

Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 275 York Avenue, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.det.2017.06.009DOI Listing
October 2017

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

N Engl J Med 2017 10 11;377(14):1345-1356. Epub 2017 Sep 11.

From the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.D.W., M.A.P., M.K.C.); Oncology Institute of Veneto Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua (V.C.-S.), European Institute of Oncology, Milan (P.F.F.), Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena (M.M.), the Immunotherapy and Somatic Cell Therapy Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (M.G.), and Istituto Nazionale Tumori Fondazione Pascale, Naples (P.A.A.) - all in Italy; University of Colorado, Denver (R.G.); Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); Aix-Marseille University, Hôpital de la Timone, Marseille (J.-J.G.), and Assistance Publique-Hôpitaux de Paris, Dermatology and Centres d'Investigation Clinique, INSERM Unité 976, Hôpital Saint-Louis, Université Paris Diderot, Paris (C.L.) - both in France; Texas Oncology-Baylor Cancer Center, Dallas (C.L.C.); University of Michigan, Ann Arbor (C.D.L.); the College of Medicine, Swansea University, Swansea (J.W.), and Royal Marsden NHS Foundation Trust, London (J.L.) - both in the United Kingdom; the Department of Dermatology, University of Essen, Essen, and the German Cancer Consortium, Heidelberg - both in Germany (D.S.); Cross Cancer Institute, Edmonton, AB (M.S.), and Princess Margaret Cancer Centre, Toronto (D.H.) - both in Canada; Universitäts Spital, Zurich, Switzerland (R.D.); Tasman Oncology Research, Southport Gold Coast, QLD (A.H.), Crown Princess Mary Cancer Centre, Melanoma Institute Australia, University of Sydney (M.S.C.), and Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals (G.V.L.), Sydney, and Peter MacCallum Cancer Centre (G.M.) and the Olivia Newton-John Cancer Research Institute, University of Melbourne (J.C.), Melbourne, VIC - all in Australia; Netherlands Cancer Institute, Amsterdam (J.H.); University Hospitals Leuven, KU Leuven, Leuven, Belgium (O.B.); General University Hospital Gregorio Marañón, Madrid (I.M.-R.); Northwestern University, Chicago (J.S.); Bristol-Myers Squibb, Princeton, NJ (D.W., L.R., R.B.); and the Dana-Farber Cancer Institute, Boston (F.S.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1709684DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706778PMC
October 2017

Targeted treatment of advanced NRAS-mutated melanoma.

Oncotarget 2017 Oct 29;8(49):84616-84617. Epub 2017 Sep 29.

Reinhard Dummer: Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.21388DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689549PMC
October 2017

A practical guide to the handling and administration of talimogene laherparepvec in Europe.

Onco Targets Ther 2017 2;10:3867-3880. Epub 2017 Aug 2.

Skin Cancer Centre/Dermatology Clinic, Universitätsspital Zürich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S133699DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546812PMC
August 2017

MEK inhibition and immune responses in advanced melanoma.

Oncoimmunology 2017 10;6(8):e1335843. Epub 2017 Aug 10.

University Hospital Zurich, Department Dermatology, Zürich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2017.1335843DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593717PMC
August 2017